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Abstract
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BACKGROUND—Hydroxyurea is an effective treatment for sickle cell anemia, but few studies
have been conducted in sub-Saharan Africa, where the burden is greatest. Coexisting conditions
such as malnutrition and malaria may affect the feasibility, safety, and benefits of hydroxyurea in
low-resource settings.
METHODS—We enrolled children 1 to 10 years of age with sickle cell anemia in four subSaharan countries. Children received hydroxyurea at a dose of 15 to 20 mg per kilogram of body
weight per day for 6 months, followed by dose escalation. The end points assessed feasibility
(enrollment, retention, and adherence), safety (dose levels, toxic effects, and malaria), and benefits
(laboratory variables, sickle cell–related events, transfusions, and survival).
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RESULTS—A total of 635 children were fully enrolled; 606 children completed screening and
began receiving hydroxyurea at a mean (±SD) dose of 17.5±1.8 mg per kilogram per day. The
retention rate was 94.2% at 3 years of treatment. Hydroxyurea therapy led to significant increases
in both the hemoglobin and fetal hemoglobin levels. Dose-limiting toxic events regarding
laboratory variables occurred in 5.1% of the participants, which was below the protocol-specified
threshold for safety. During the treatment phase, 20.6 dose-limiting toxic effects per 100 patientyears occurred, as compared with 20.7 events per 100 patient-years before treatment. As compared
with the pretreatment period, the rates of clinical adverse events decreased with hydroxyurea use,
including rates of vaso-occlusive pain (98.3 vs. 44.6 events per 100 patient-years; incidence rate
ratio, 0.45; 95% confidence interval [CI], 0.37 to 0.56), nonmalaria infection (142.5 vs. 90.0
events per 100 patient-years; incidence rate ratio, 0.62; 95% CI, 0.53 to 0.72), malaria (46.9 vs.
22.9 events per 100 patient-years; incidence rate ratio, 0.49; 95% CI, 0.37 to 0.66), transfusion
(43.3 vs. 14.2 events per 100 patient-years; incidence rate ratio, 0.33; 95% CI, 0.23 to 0.47), and
death (3.6 vs. 1.1 deaths per 100 patient-years; incidence rate ratio, 0.30; 95% CI, 0.10 to 0.88).
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CONCLUSIONS—Hydroxyurea treatment was feasible and safe in children with sickle cell
anemia living in sub-Saharan Africa. Hydroxyurea use reduced the incidence of vaso-occlusive
events, infections, malaria, transfusions, and death, which supports the need for wider access to
treatment. (Funded by the National Heart, Lung, and Blood Institute and others; REACH
ClinicalTrials.gov number, NCT01966731.)
SICKLE HEMOGLOBINOPATHIES ARE COMmon and life-threatening genetic disorders.
Homozygous hemoglobin S (HbSS) is the most severe genotype, and together with
hemoglobin Sβ0 thalassemia, is called sickle cell anemia.1 On deoxygenation, erythrocytes
become sickle-shaped, rigid, adhesive, and prone to lysis; blood flow is blocked within small
N Engl J Med. Author manuscript; available in PMC 2019 July 10.
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vessels, leading to ischemic tissue injury.1 In the United States, approximately 100,000
persons are affected,2 most of whom have numerous acute and chronic medical
complications that lead to poor quality of life and early death.1,3 On a global scale, the
incidence of sickle hemoglobinopathies is greatest in sub-Saharan Africa, with more than
300,000 babies with sickle cell disease born annually, representing approximately 1% of
births in the region.4

Author Manuscript

In high-resource settings such as the United States and Europe, as well as Jamaica and other
Caribbean settings, the early identification of children with sickle cell anemia by means of
neonatal screening allows for comprehensive care that includes simple, effective, and
lifesaving interventions with penicillin prophylaxis, pneumococcal immunizations, and
caregiver education.5-7 The advent of routine transcranial Doppler screening to identify
children at risk for stroke, along with access to safe erythrocyte transfusions, has further
contributed to marked decreases in morbidity.8 To date, however, very few settings in subSaharan Africa have established screening programs for sickle cell anemia, and specialized
treatment is available at only a few large, urban centers.
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Hydroxyurea was first shown to induce fetal hemoglobin production more than 30 years
ago9 and is now a Food and Drug Administration–approved treatment for sickle cell anemia
in both children (Siklos, Addmedica) and adults (Hydrea and Droxia, Bristol-Myers
Squibb). By means of the induction of fetal hemoglobin and other beneficial changes,
including mild myelosuppression, hydroxyurea therapy has been shown to have clinical
efficacy in reducing the incidence of acute vaso-occlusive events,10,11 ameliorating chronic
organ damage,12 and prolonging survival.13,14 Evidence-based guidelines from the National
Heart, Lung, and Blood Institute recommend offering hydroxyurea treatment to persons with
sickle cell anemia as early as 9 months of age.15
Whether hydroxyurea will be safe and effective in Africa is unclear. Coexisting conditions
such as malaria, other infectious diseases that are endemic to the area, and malnutrition may
increase the incidence of toxic effects and limit treatment responses. We conducted an
international trial, Realizing Effectiveness across Continents with Hydroxyurea (REACH),
to investigate the feasibility, safety, and benefits of hydroxyurea treatment for children with
sickle cell anemia living in sub-Saharan Africa.

METHODS
TRIAL DESIGN

Author Manuscript

We designed this phase 1–2, open-label, international trial to assess the feasibility, safety,
and benefits of hydroxyurea treatment in young children with sickle cell anemia living in
sub-Saharan Africa. The two-stage trial design has been described previously16 and included
a built-in pause in enrollment to ensure the safety of the initial dose level (Fig. S1 in the
Supplementary Appendix, available with the full text of this article at NEJM.org). Children 1
to 10 years of age were recruited at four clinical trial sites in sub-Saharan Africa (Hospital
Pediátrico David Bernardino in Luanda, Angola; Centre Hospitalier Monkole in Kinshasa,
Democratic Republic of Congo; Kilifi District Hospital in Kilifi, Kenya; and Mbale
Regional Referral Hospital in Mbale, Uganda), with a goal of treating 150 participants per
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site with once-daily oral hydroxyurea. At each site, enrollment was paused to allow for the
evaluation of the 3-month incidence of hematologic toxic effects among the first 53
participants enrolled.16
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The protocol (available at NEJM.org) was designed by the authors and approved by all
appropriate institutional review boards or ethics committees, as well as by national
regulatory groups. A parent or legal guardian provided written informed consent for each
participant to enroll and begin the screening process. A full list of the investigative teams,
including the physicians, nurses, pharmacists, and laboratory and data personnel who
received specific protocol training, is provided in the Supplementary Appendix. Local trial
teams collected the data, which were monitored and analyzed by the data management
center. The first draft of the manuscript was written by the first and last authors, with
contributions by all the authors. All the authors made the decision to submit the manuscript
for publication. The sponsors had no oversight or involvement in data collection and analysis
or in the writing and submission of the manuscript. The last author vouches for the accuracy
and completeness of the data and for the fidelity of the trial to the protocol.
DRUG TREATMENT AND DOSE ESCALATION
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Hydroxyurea capsules were donated by Bristol-Myers Squibb, which had no role in the trial
design or conduct, the data collection or analysis, or the manuscript preparation or review.
After a 2-month screening period that was used to collect pretreatment clinical and
laboratory data, the starting dose of hydroxyurea was 15 to 20 mg per kilogram of body
weight per day. After 6 months of treatment, the hydroxyurea dose was escalated by 2.5 to
5.0 mg per kilogram per day every 2 months on the basis of peripheral-blood counts to
determine a maximum tolerated dose, which was defined as a stable daily dose that caused
mild bone marrow suppression without toxic effects — typically, an absolute neutrophil
count of less than 4000 per cubic millimeter. To ensure the safety of the participants, the
dose level was monitored at each visit by trial staff, who entered the results of the complete
blood count and reticulocyte count into an interactive online calculator tool before the drug
was dispensed.
END POINTS

Author Manuscript

The primary safety end point was hematologic dose-limiting toxic effects in the first 3
months of hydroxyurea treatment in the first 133 children enrolled at each clinical trial site;
the expected and allowable rates of this end point were 20% and 30%, respectively, on the
basis of published toxicity data, with type I and II error rates of 10%.16 Protocol-specified
thresholds for toxic effects involving laboratory variables included a hemoglobin level of
less than 4.0 g per deciliter, an absolute neutrophil count of less than 1000 per cubic
millimeter, an absolute reticulocyte count of less than 80,000 per cubic millimeter unless the
hemoglobin level was more than 7.0 g per deciliter, and a platelet count of less than 80,000
per cubic millimeter. Additional trial end points included assessments of feasibility
(enrollment, retention, and adherence), safety (dose levels, toxic effects, and malaria), and
benefits (laboratory variables, sickle cell–related events, transfusions, and survival).
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All the trial data were collected and entered into a REDCap Internet-based data-capture
system. Separate REDCap environments were developed in English, Portuguese, and
French, which were the official languages at each clinical site.16 Data on clinical adverse
events of grade 2 or higher were collected during both the screening (pretreatment) phase
and the treatment phase. Trial monitoring used a remote system and on-site evaluations.
Data on adverse events were collected and curated, with review of source documentation
whenever available. Deaths were further evaluated with the use of the World Health
Organization (WHO) verbal autopsy form that has previously been validated for children
with sickle cell anemia.17
STATISTICAL ANALYSIS

Author Manuscript

The Simon two-stage design for the primary safety end point (hematologic dose-limiting
toxic effects in the first 3 months of hydroxyurea treatment) has been described previously.16
Secondary end points regarding feasibility, safety, and benefits were summarized with means
and standard deviations or percentages, as appropriate. We used a competing-risk approach
to estimate the cumulative incidence of death or withdrawal. Laboratory values at baseline
and at 12 months were compared by Student’s t-test. Rates of clinical adverse events during
the pretreatment phase and during the treatment phase were presented as the number of
events per 100 patient-years and compared by the incidence rate ratio with 95% confidence
intervals, all of which were calculated from Poisson regression with the use of generalized
estimating equations to account for clustering and overdispersion. A similar approach was
used to show the effect of increasing treatment duration, with events and time at risk during
treatment divided into consecutive 6-month intervals. There were no adjustments for
multiple comparisons. All the statistical analyses were performed with the use of R software,
version 3.4.4.
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RESULTS
ENROLLMENT AND RETENTION
All four trial sites proceeded to the second stage of the trial and met their enrollment goals.
A total of 635 children had consent provided by a parent or guardian and entered screening,
606 children completed screening and began receiving hydroxyurea treatment, and 600
children (99.0%) completed 3 months of the trial treatment (Fig. 1). The overall retention
rate in the trial was 94.2% at 3 years of treatment (Fig. 2). A total of 33 children (5.4%)
withdrew from the trial after treatment initiation. More than 98% of the trial visits were
completed, including 91% within the scheduled visit window.

Author Manuscript

HYDROXYUREA DOSE
The initial mean (±SD) dose of hydroxyurea that was administered was 17.5±1.8 mg per
kilogram per day, which was within the protocol-directed starting dose range of 15 to 20 mg
per kilogram per day. The initial dose was fixed for 6 months in all the participants to allow
for the assessment of laboratory and clinical adverse events. Dose escalation began at month
6, and to date, 515 children (85.0%) have reached a mean maximum tolerated dose of
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22.5±4.9 mg per kilogram per day, with the dose ranging from 18.9±4.2 mg per kilogram
per day in Angola to 25.3±4.8 mg per kilogram per day in Uganda. The mean time to
reaching the maximum tolerated dose was 11±4 months, and the mean overall treatment
duration was 29±9 months. The rate of adherence to medication was assessed at each
scheduled visit, and more than 90% of assessments documented no missed doses. A brief
drug shortage between February and April 2016 affected the administration of the
medication at three sites but had no influence on the primary end point (Table S1 in the
Supplementary Appendix).
ADVERSE EVENTS

Author Manuscript

Laboratory monitoring at scheduled visits and at unscheduled visits for illness identified
dose-limiting toxic effects during the screening phase (a total of 2012 complete blood counts
were performed over a period of 111 patient-years) and during the treatment phase (a total of
13,589 complete blood counts were performed over a period of 1469 patient-years).
Hematologic dose-limiting toxic effects during the first 3 months (the primary safety end
point) occurred in 5.1% of the participants overall, with the rate at each site being well
below the protocol-specified thresholds for toxic events regarding laboratory variables. The
rates of these safety events differed across sites, ranging from 0.8% to 8.3% (P = 0.01 by
Fisher’s exact test) (Table S2 in the Supplementary Appendix), and the random-effects
pooled estimate was 4.5% (95% confidence interval [CI], 2.3 to 8.8). No significant
differences between the screening and treatment phases were found with regard to the
individual laboratory toxic-effect variables (Table 1), but slight differences were noted
between sites (data not shown).
LABORATORY BENEFITS
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Laboratory variables at baseline revealed anemia with expected leukocytosis and
reticulocytosis (Table 2). After 1 year of hydroxyurea treatment, the participants had
significant increases in the hemoglobin level (increase of 1.0 g per deciliter; 95% CI, 0.8 to
1.0), the mean corpuscular volume (increase of 13 fl; 95% CI, 12 to 13), and the fetal
hemoglobin level (increase of 12.5%; 95% CI, 11.8 to 13.1). During hydroxyurea treatment,
the white-cell count, absolute neutrophil count, and absolute reticulocyte count significantly
decreased, reflecting the intended mild bone marrow suppression, and these effects were
sustained over time (Table 2). Similar results were recorded at each individual clinical trial
site (data not shown).
CLINICAL BENEFITS

Author Manuscript

Comparison of event rates between the screening and treatment phases revealed significant
reductions in the incidence of all clinical adverse events (308.4 vs. 170.7 events per 100
patient-years; incidence rate ratio, 0.54; 95% CI, 0.48 to 0.62) and serious adverse events
(10.8 vs. 4.4 events per 100 patient-years; incidence rate ratio, 0.47; 95% CI, 0.25 to 0.90)
during hydroxyurea treatment. The investigators did not consider any of the adverse events
or serious adverse events to be related to hydroxyurea treatment.
The overall rate of sickle cell–related events was significantly reduced (114.5 vs. 53.0 events
per 100 patient-years; incidence rate ratio, 0.47; 95% CI, 0.38 to 0.57), and the rates of vaso-
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occlusive pain and the acute chest syndrome were both reduced (Table 1). The rates of
infection also declined, including rates of nonmalaria infection (142.5 vs. 90.0 events per
100 patient-years; incidence rate ratio, 0.62; 95% CI, 0.53 to 0.72) and severe infection of
grade 3 or higher (28.9 vs. 8.0 events per 100 patient-years; incidence rate ratio, 0.28; 95%
CI, 0.19 to 0.42).
EFFECTS ON SURVIVAL

Author Manuscript

Analyses of additional key clinical events revealed significant reductions during
hydroxyurea treatment in the rate of malaria infections (46.9 vs. 22.9 events per 100 patientyears; incidence rate ratio, 0.49; 95% CI, 0.37 to 0.66), blood transfusion (43.3 vs. 14.2
events per 100 patient-years; incidence rate ratio, 0.33; 95% CI, 0.23 to 0.47), and death (3.6
vs. 1.1 events per 100 patient-years; incidence rate ratio, 0.30; 95% CI, 0.10 to 0.88). When
grouped into 6-month time intervals, the rates of multiple life-threatening clinical events
declined rapidly after the initiation of hydroxyurea therapy and dose escalation, with a
sustained or improved benefit. Reductions in event rates over time were noted for all sickle
cell–related clinical events, malaria, vaso-occlusive pain, transfusion, the acute chest
syndrome, and death from any cause (Fig. 3).

DISCUSSION
In this trial involving children with sickle cell anemia living in sub-Saharan Africa, we
found that hydroxyurea treatment was feasible, reasonably safe, and had both laboratory and
clinical benefits. Specifically, as compared with pretreatment rates, the rates of clinical
events, including vaso-occlusive pain, infection, malaria, transfusion, and death, declined
after 1 year of hydroxyurea treatment.

Author Manuscript

Enrollment was robust at all the clinical trial sites, with enthusiasm and support from local
clinical research teams and populations of patients, which showed the feasibility of
conducting a large-scale clinical trial in sub-Saharan Africa. Hematologic dose-limiting
toxic effects during the first 3 months of treatment (the primary safety end point) occurred in
only a small number of participants, and the hydroxyurea dose was then safely escalated
toward a maximum tolerated dose, similar to treatment protocols in the United States.15
Expected hematologic benefits occurred, with significant increases in the hemoglobin and
fetal hemoglobin levels. Significant reductions were observed in the incidence rates of sickle
cell–related clinical events, including vaso-occlusive pain, and major clinical events
including infection, malaria, transfusion, and death. No serious adverse events or deaths
were considered by the investigators to be related to hydroxyurea treatment (Tables S3 and
S4 in the Supplementary Appendix).
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In the United States and Europe, hydroxyurea has emerged as a potent, disease-modifying
therapy with regulatory approvals for use in both children and adults. Although the primary
mode of action of hydroxyurea is through the induction of fetal hemoglobin, this drug has
multiple salutary effects on erythrocytes, leukocytes, and even endothelium that make it a
beneficial oral treatment for this life-threatening disease, especially at the maximum
tolerated dose.18 The WHO includes hydroxyurea on its Model Lists of Essential Medicines
for children and adults for the treatment of sickle hemoglobinopathies,19,20 which provides
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an impetus for widespread use on a global scale. To date, however, few studies have been
completed in sub-Saharan Africa or other low-income settings where the burden of sickle
cell disease is greatest.21 In addition to several small studies of hydroxyurea conducted in
Nigeria,22-24 the Novel Use of Hydroxyurea in an African Region with Malaria (NOHARM)
trial was a randomized, double-blinded, placebo-controlled trial that was conducted at a
single, large, urban site in Uganda, which showed that the rates of malaria were not higher
with hydroxyurea than with placebo.25 However, the overall incidence of malaria in the
NOHARM trial was very low, whereas the participants in the REACH trial lived in urban
and rural areas of Africa that have a much higher incidence of malaria than Kampala,
Uganda, where the NOHARM trial was conducted.
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With full enrollment, high rates of adherence to trial visits and medication use, and a
retention rate of nearly 95% in the trial over a period of 3 years, our trial showed that
hydroxyurea treatment was both feasible and safe in sub-Saharan Africa. Despite frequent
laboratory monitoring, dose-limiting toxic effects were uncommon in the first 3 months of
treatment, and then the incidence did not increase further (Table 1). After 6 months of fixeddose hydroxyurea therapy, dose escalation was not associated with unacceptable side effects
or with toxic effects regarding laboratory variables and reached daily doses that were similar
to those reported in the United States.26,27 Our results indicate that a daily dose of
approximately 20 mg per kilogram per day was reasonably effective and not associated with
dose-limiting toxic effects. The trial was not designed to determine the appropriate amount
or frequency of laboratory monitoring.
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The laboratory benefits of hydroxyurea treatment were evident, despite relative malnutrition
in the REACH cohort, as compared with WHO childgrowth standards and with populations
of patients with sickle cell disease in the United States and Europe. Expected significant
increases were observed in both the hemoglobin and fetal hemoglobin levels, along with
significant decreases in the absolute neutrophil and reticulocyte counts, and these changes
were sustained over time (Table 2). The mean increase in the hemoglobin level of 1 g per
deciliter, despite suboptimal nutrition and ongoing risks of malaria and other infections, is
important because the hemoglobin level is a well-established predictor of adverse outcomes
in children with sickle cell anemia.28 Within 6 months after the start of treatment, expected
clinical benefits were also observed with regard to sickle cell–related events such as pain and
the acute chest syndrome, as well as all severe (grade ≥3) adverse events.
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The benefits of hydroxyurea therapy with regard to malaria infections were significant —
with a rate reduction of more than 50% — and were not predicted before the trial (Table 1),
despite the lack of malaria chemoprophylaxis programs at all the clinical sites. This benefit
was especially notable after 12 months of treatment, so it may reflect known inhibitory
effects of fetal hemoglobin,29 more than direct effects by hydroxyurea,30 on parasite growth.
The importance of this effect should be evident for sub-Saharan Africa, where Plasmodium
falciparum malaria is a major killer of children and is especially lethal in those with sickle
cell anemia.31 In a finding that perhaps reflects the decrease in the incidence of malaria,
there was a significant reduction in the incidence of transfusions (Table 1), which is
important because of the general lack of safe blood supply across Africa.32
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This trial showed a significant reduction in all-cause mortality in this young cohort (Table
1). This effect reflects the combined effect of fewer severe sickle cell–related clinical
complications, infections, malaria, and possibly transfusions. However, because the REACH
trial did not include a placebo control, the survival benefit could be due to hydroxyurea use
but also to better overall care, since the participants had frequent visits while they were
receiving treatment. However, these findings are similar to those of previous reports that
have shown an effect of hydroxyurea therapy on survival.13,14,33,34
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A limitation of this trial was the open-label treatment design without randomization or a
placebo control, which was a decision that was based on strong opinions from the local
ethics boards. However, the design fully addressed the key end points of feasibility and
safety, showing that hydroxyurea could be administered in low-resource settings. All the
participants received good care with close monitoring, which probably contributed to better
outcomes that were unrelated to hydroxyurea treatment; additional studies will be needed to
confirm sustained benefits with less monitoring. Strengths of this trial included the
following: the international design; the dosing algorithm of a fixed dose followed by
escalation to the maximum tolerated dose; the use of an electronic-capture system for data
entry; and the availability of an online dose calculator to help ensure the safety of the
participants. Long-term follow-up of this African cohort is ongoing for the investigation of
growth and development and possible effects on organ function and fertility.
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In conclusion, our results show that daily hydroxyurea treatment was feasible and safe for
children with sickle cell anemia in sub-Saharan Africa. Moreover, hydroxyurea treatment
reduced the rates of painful events, infection, malaria, transfusion, and death. Despite the
recognition that 50 to 90% of affected children in Africa die before the age of 5 years,35
sickle cell anemia remains a neglected disease for which safe and effective treatment options
are needed.36 As countries in sub-Saharan Africa begin newborn screening programs to
identify children with sickle cell anemia,37-39 wider access to hydroxyurea may provide a
simple and inexpensive oral medication that can alter the disease course and prolong
survival.
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Figure 1. Screening, Enrollment, and Follow-up of the Participants.

Author Manuscript

The numbers of patients who withdrew from the trial or died are from the group of patients
who completed treatment up to the respective time point.
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Figure 2. Retention of Participants in the Trial.

The shaded area represents the 95% confidence interval for death or withdrawal from the
trial. The inset shows the same data on an enlarged y axis.
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Figure 3. Adverse Events before and during Hydroxyurea Treatment.

Error bars indicate 68% confidence intervals, which correspond to approximately 1 standard
error.
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